PAVM and LUCD Related Headlines
Go Back- PAVmed raises $45 million, eliminates convertible securities overhang
- PAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities
- Lucid Diagnostics receives VA contract for esophageal cancer test
- Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard®
- PAVmed conducts 1-for-30 reverse stock split to meet Nasdaq requirement
- PAVmed Announces Reverse Stock Split
- Lucid Diagnostics reports real-world data from 12,000 esophageal tests
- Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection
- Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree
- Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
- PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results
- Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results
- PAVmed to Hold a Business Update Conference Call and Webcast on November 13, 2025
- Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025
- Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit
- Lucid Diagnostics names John Palumbo to board of directors
- Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors
- Lucid Diagnostics names Danielle Scelfo as market access chief
- Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs
- Lucid Diagnostics closes $28.8 million stock offering
- Lucid Diagnostics Announces Closing of Public Offering of Common Stock
- Lucid Diagnostics prices 25 million share offering at $1.00 per share
- Lucid Diagnostics Announces Pricing of Public Offering of Common Stock
- Lucid Diagnostics announces proposed public stock offering
- Lucid Diagnostics announces proposed public stock offering
- Lucid Diagnostics Announces Proposed Public Offering of Common Stock
- Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025
- Lucid Diagnostics to Participate in the Cantor Global Healthcare Conference 2025
- PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology
- PAVmed Provides Business Update and Reports Second Quarter 2025 Financial Results
- Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results
- Lucid Diagnostics to Participate in Upcoming Investor Conferences
- PAVmed to Hold a Business Update Conference Call and Webcast on August 14, 2025
- PAVmed gets 180-day extension from NASDAQ to meet $1 minimum bid price
- Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025
- PAVmed Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
- MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test
- Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test
PAVM and LUCD Related Press Releases
Go Back- PAVmed Closes Preferred Stock and Senior Secured Note Financings, Eliminating All Previously Outstanding Convertible Securities
- Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard®
- PAVmed Announces Reverse Stock Split
- Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection
- Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree
- Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
- PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results
- Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results
- PAVmed to Hold a Business Update Conference Call and Webcast on November 13, 2025
- Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025
- Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit
- Lucid Diagnostics Appoints Healthcare Industry Veteran John R. Palumbo to Board of Directors
- Lucid Diagnostics Appoints Danielle Scelfo as Senior Vice President, Market Access & Government Affairs
- Lucid Diagnostics Announces Closing of Public Offering of Common Stock
- Lucid Diagnostics Announces Pricing of Public Offering of Common Stock
- Lucid Diagnostics Announces Proposed Public Offering of Common Stock
- Lucid Diagnostics to Host Investor Call on Monday, September 8, 2025
- Lucid Diagnostics to Participate in the Cantor Global Healthcare Conference 2025
- PAVmed Signs Letter of Intent to License Groundbreaking Endoscopic Esophageal Imaging Technology
- PAVmed Provides Business Update and Reports Second Quarter 2025 Financial Results
- Lucid Diagnostics Provides Business Update and Reports Second Quarter 2025 Financial Results
- Lucid Diagnostics to Participate in Upcoming Investor Conferences
- PAVmed to Hold a Business Update Conference Call and Webcast on August 14, 2025
- Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on August 13, 2025
- PAVmed Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule
- MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test
- Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test
